Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gardasil Faces Another Safety Study, Looking At Four Rare AEs

This article was originally published in The Pink Sheet Daily

Executive Summary

Sentinel will consider data from 3m doses of Merck's nine-valent HPV vaccine.

You may also be interested in...



Merck’s Gardasil Adds Serotypes; Boosting Vaccinations Seems Bigger Challenge

Promotion strategy likely to remain same after nine-valent HPV vaccine wins FDA approval; Merck may need help from the CDC to overcome cultural barriers to adoption.

Cervarix Gets One Up On Gardasil In Cross-Protection: HPV-31 In FDA Approval

GlaxoSmithKline's effort to make its bivalent human papillomavirus vaccine, Cervarix, into a multivalent product through proof of cross protection against additional HPV virus strains achieved a partial, one-virus, success at FDA

Pink Sheet Podcast: Breakthrough Therapy CRLs, Statins While Pregnant, COVID-19 And Clinical Trials

Pink Sheet reporters and editors discuss increasing complete response letters for breakthrough designees, FDA changing course on statin use during pregnancy, and efforts to use pandemic innovations to improve clinical research going forward.

Topics

Related Companies

UsernamePublicRestriction

Register

PS079434

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel